Acino opened a new pharmaceutical manufacturing plant in Miesbach, Germany, in August 2012. The plant, owned and managed by Acino Holding, produces commercial quantities of transdermal rivastigmine patches.
US-based analytical technology company Agilent Technologies has opened a multi-structure pharmaceutical manufacturing plant in Frederick, Weld County, Colorado. The facility's construction began in October 2016 and it was opened in June 2019.
Ireland-based pharmaceutical company Allergan, which produces eye-care and dermatological products, began an expansion of its manufacturing facility in Texas Central Park in Waco, Texas, in April 2016.
Iceland-based biopharmaceutical company Alvotech officially opened a biosimilar facility in Reykjavik on 8 June 2016. The facility will be dedicated to the production of biosimilars of monoclonal antibodies (mAbs).
AstraZeneca started production at its a new manufacturing facility at Taizhou in Jiangsu province of China in October 2014. The facility manufactures intravenous and oral solid medicines for the Chinese market.
US-based pharmaceutical company Athenex, in partnership with the State University of New York Polytechnic Institute (SUNY Polytechnic Institute), is building a high pharmacy oncology manufacturing facility in Dunkirk, New York, to manufacture sterile high-potency oncology drugs.
Baxter BioPharma Solutions is a contract manufacturer of pre-filled syringes, vials and cartridges for the packaging of vaccines and drugs to treat chronic conditions such as rheumatoid arthritis and multiple sclerosis.
The Bigelow Centre for Blue Biotechnology, (BCBB) is a new research centre built in East Boothbay, Maine, US. It conducts frontline research on applying the ocean's microbial ecosystems to biopharmaceuticals.
BioCentriq is a clinical manufacturing facility for cell and gene therapies under development at the New Jersey Institute of Technology (NJIT) university in Newark, New Jersey, US, the first cell and gene therapy development and manufacturing centre established on a university campus in the country.
The construction of a research facility for the Research Institute of Molecular Pathology (IMP) at the Vienna Biocentre in the third district of Vienna, Austria, fully sponsored by Boehringer Ingelheim, began in March 2015.
The construction of the Brigham translational research and clinical facility, also known as the Brigham Building for the Future (BBF), was initiated by the Brigham and Women’s Hospital (BWH) in June 2013.
The Bristol Myers Squibb East Syracuse campus is more than 60 years old. Launched in 1943, the pharmaceutical manufacturing facility made nearly 70% of the penicillin produced in the world until the mid-2000s.
US-based pharmaceutical company Bristol Myers Squibb (BMS) is to build a new Chimeric Antigen Receptor T-cell (CAR-T) therapy manufacturing facility at the Leiden Bio Science Park in Leiden, Netherlands.
In October 2015, Tianjin CanSino Biotechnology (CanSino) began building its first fully integrated Ebola vaccine manufacturing facility in the Tianjin Economic-Technological Development Area (TEDA) west zone in China.
In June 2015, US-based pharmaceutical company Capsugel finished building a pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its existing research and development (R&D) facility in Bend City, Oregon.
Cascade Chemistry, an American pharmaceutical contract development and manufacturing organisation (CDMO), is constructing new facilities to expand the current good manufacturing practices (cGMP) pharmaceutical manufacturing capacity of its Eugene site in the US.
Catalent Biologics’ manufacturing facility in Anagni, Italy will serve as the launch facility for the large-scale production and supply of the University of Oxford’s Covid-19 vaccine candidate, AZD1222.
The Chao Center for Industrial Pharmacy and Contract Manufacturing is based in Purdue Research Park, West Lafayette, Indiana and linked to the Purdue University department of Industrial and Physical Pharmacy and Pharmaceutical Sciences.
In October 2015, Japanese pharmaceutical company Chugai Pharmaceutical announced its decision to build a plant for manufacturing antibody active pharmaceutical ingredients (APIs) at its existing Ukima Plant in Kita-ku, Tokyo.
Cobra Biologics, a contract development and manufacturing organisation (CDMO), is expanding its manufacturing facility located in Matfors, Sundsvall, Sweden, with an estimated investment of €20m ($22.47m).
In April 2015, Puerto Rican pharmaceutical company Coquí RadioPharmaceuticals (Coquí) completed the schematic design for a medical isotope production (MIP) facility in Alachua County, Florida. Coquí has started work on the detailed design for the facility.
The Djavad Mowafaghian Centre for Brain Health located near the University of British Columbia (UBC) hospital along Wesbrook Mall on the UBC campus in Vancouver, Canada, was inaugurated in February 2014.
Evergreen Theragnostics, a radiopharmaceutical contract development and manufacturing organisation (CDMO) based in New Jersey, US, is developing a state-of-the-art radiopharmaceutical manufacturing facility in New Jersey, US.
US-based healthcare company Grail is building a state-of-the-art laboratory facility in the Research Triangle Park (RTP), North Carolina. The facility will primarily function as a commercial cancer lab for sample processing.
In June 2015, biopharmaceutical company Green Cross Biotherapeutics (GCBT) broke ground on the construction of Canada’s first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Montreal, Quebec.
Hitachi Chemical Advanced Therapeutics Solutions (HCATS) opened its new manufacturing facility in New Jersey, US, in January 2020, developed to meet the demand for cell and gene therapy manufacturing services.
Integrated DNA Technologies (IDT) opened a manufacturing facility in North Carolina's Research Triangle Park in the US in May 2020 for supporting research and testing efforts related to the Covid-19 pandemic.
In May 2019, ILC Dover opened a manufacturing facility in Ireland to produce the company’s pharmaceutical and biopharmaceutical product lines. The plant is designed to strengthen the company's single-use powder handling solutions business.
Isis Pharmaceuticals inaugurated a new research and development (R&D) facility at Carlsbad in California, USA in September 2011. The new facility is provided with sophisticated drug discovery and development facilities.
In May 2016, Taiwan-based biopharmaceutical company JHL Biotech officially inaugurated a single-use bioprocessing technology-based KUBio™ modular biopharmaceutical manufacturing facility in Wuhan, China.
KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) is located in Durban, South Africa. K-RITH was founded in 2008 by the Howard Hughes Medical Institute (HHMI) and the University of KwaZulu-Natal (UKZN).
Lakes BioScience is planning to build a pharmaceutical manufacturing plant in Ulverston, Cumbria, UK. The new facility will be built as part of the company’s Project Apex, an initiative to create a customer-focused contract development and manufacturing organisation (CDMO).
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at its facility in Madison, Wisconsin, US, in September 2020.
Morphotek, a subsidiary of Eisai Co, opened a pilot manufacturing plant for the production of antibodies for early phase clinical trials of biologics in Welsh Road, Exton, Pennsylvania, US, in August 2012.
In August 2013, NanoViricides began building a clinical-scale current good manufacturing practice (cGMP) production plant at the industrial-commercial zone on the Route 8 Corridor in Shelton City, Connecticut.
The largest city in the north-western United States, Seattle, has become a hub for pharmaceutical research activity with the world's leading pharmaceutical companies establishing their research and development (R&D) centres there.
In September 2015, US-based pharmaceutical start-up Oxford Pharmaceuticals broke ground on the construction of a generic drug manufacturing and distribution facility in Jefferson County, Birmingham, Alabama.
Parsolex, a contract development and manufacturing organisation based in the US, partnered with Bosch Packaging Technology to equip its West Lafayette facility with the latest pharmaceutical packaging technologies, in November 2019.
US-based pharmaceutical company Pfizer began building a biologics clinical manufacturing facility at its existing manufacturing facility in Andover, Massachusetts, in June 2016. The new facility will be used for producing high-quality, complex biologics and vaccines and is expected to come online by January 2019.
Pfizer's OSP4 synthesis facility at Ringaskiddy began construction in 1998 in response to anticipated global demand for Sildenafil citrate, the active pharmaceutical ingredient (API) of Viagra. The facility began production in mid-2001.
Piramal Pharma Solutions (PPS) is expanding its manufacturing facility in Riverview, Michigan, with an investment of approximately $32m to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).
Regis Technologies, a US-based contract development and manufacturing organisation (CDMO), completed the expansion of its custom active pharmaceutical ingredients (APIs) development laboratory facilities in Morton Grove, Illinois, in February 2021.
Rentschler Biopharma is carrying out an expansion of its recently acquired biopharmaceutical manufacturing facility located in Milford, US. The project is part of the company’s plan to expand its business in the US and Europe.
Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support the production of its pipeline of lentivirus and adeno-associated virus (AAV) gene therapies.
In October 2018, Samsung BioLogics opened its third biologics manufacturing plant in Songdo, South Korea. The plant made Samsung Group one of the world’s largest biologics contract manufacturing operators (CMOs).
Switzerland-based biopharmaceuticals supplier Lonza and French life sciences firm Sanofi have established a joint venture (JV) to set up a large-scale biologics production facility in Visp, Switzerland.
Saudi Vaccine and Biomanufacturing Centre is a research facility being constructed at the KAUST Research and Technology Park in Saudi Arabia for the development of vaccines and biopharmaceutical products.
Servier Pharmaceuticals is constructing Servier Paris-Saclay research institute, a new research and development hub in the Paris-Saclay cluster, France, which is one of the world’s top eight invention clusters.
China-based pharmaceutical outsourcing partner ShangPharma has signed a deal with the Qidong Biopharma Industrial Zone in Qidong, China, to build a biologics manufacturing and pre-clinical research facility.
US-based radiopharmaceutical company SHINE Medical Technologies is to build a medical isotope production facility in Veendam, Netherlands. The facility is intended to provide a reliable, flexible supply of a range of vital medical tracers and cancer treatment elements for customers in Europe.
Shionogi & Co's new pharmaceutical research facility is located in Toyonaka City in Osaka, Japan. The new facility was opened in August 2011. It is equipped with drug discovery research laboratories and laboratory equipment, as well as information technology capabilities.
Located in Doha, Qatar, Sidra Medical and Research Center will be an ultramodern, all-digital academic medical centre, designed and planned to the highest international standards in technology, science and patient care.
Sofrigam opened its factory in Arras, France, in January 2008. The factory is used to test and manufacture temperature-controlled logistics packaging for the European market, and produces cold chain solutions for companies including GSK, Astra Zeneca and Pfizer.
Taysha Gene Therapies will build a new current Good Manufacturing Practices (cGMP) gene therapy manufacturing facility in Durham, North Carolina, US to support preclinical, clinical and commercial cGMP production of its broad gene therapy pipeline drugs.